Ropinirole treatment for restless legs syndrome

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Restless legs syndrome (RLS) is a chronic neurological disorder associated with sleep disturbance. Ropinirole, a non-ergot dopamine agonist, has been widely studied for the treatment of moderate-to-severe primary RLS in a comprehensive clinical development program. In these studies, ropinirole was effective in significantly improving the symptoms of RLS, compared with placebo, in patients with moderate-to-severe primary RLS. These improvements are supported by data from individual studies, as well as by pooled analyses. Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements; and on subjective measures of sleep, ropinirole was generally well tolerated. A newly developed extended-release formulation of ropinirole may benefit patients who warrant an extended duration of therapy.

Original languageEnglish (US)
Pages (from-to)655-664
Number of pages10
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number5
StatePublished - May 2008


  • Dopamine agonist
  • Restless legs syndrome
  • Ropinirole

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Ropinirole treatment for restless legs syndrome'. Together they form a unique fingerprint.

Cite this